Overview

Study of SBP-101 in Pancreatic Cancer

Status:
Completed
Trial end date:
2017-10-01
Target enrollment:
Participant gender:
Summary
This phase 1 first-in-human study evaluates safety and tolerability of SBP-101 in subjects with previously treated pancreatic ductal adenocarcinoma and will identify the maximum tolerated dose (MTD). In addition, this study will also assess the pharmacokinetic (PK) profile and preliminary efficacy of SBP-101.
Phase:
Phase 1
Details
Lead Sponsor:
Panbela Therapeutics, Inc.
Sun BioPharma Inc